The publication of an advantageous compound as a pharmaceutical ingredient for the treatment of diseases related to class 11b dehydrogenase, such as dementia, schizophrenia, depression, pain (especially neuropathic or fibrotic pain),Diabetes (especially type 2 diabetes)Insulin resistance, etc.: it is found that a bicyclic heterocyclic compound (when cyclohexane is fused with a 5-6 member monocyclohexane, only one of which is a heterogenous nitrogen atom) is replaced by an acid group such as a group. (straight) similar aroilamino or similar pharmaceutically acceptable salts have excellent inhibitory effect on 11b-hsd1. Therefore, this bicyclic heterocyclic compound can be used to treat dementia, schizophrenia, depression, pain (especially neuropathic pain or fibrosis).Diabetes (especially type 2 diabetes)1. Insulin resistance and other. Requirements 1: compound represented by formula (1) or acceptable salt of drug； [the symbol in the formula indicates: Ring A: a single periodic heteromorphism of 5 to 6 members, which can be replaced, and only the nitrogen atom is the heteroatom； the atom existing in the position where the ring merges with the adjacent ring is the carbon atom, R1: low tar, halo low tar, or substituted cyclopentyl, R2: halo or low tar, R3: arilo, isohalo or low tar isohalo；Here, each arilo and heretic represented by R 3 can be replaced, N: the whole 0-3 and a dotted line represent a simple link or a double link].Dar a conocer un compuesto ventajoso como ingrediente activo de una composición farmacéutica para el tratamiento de enfermedades relacionadas con la 11b-hidroxiesteroide deshidrogenasa tipo 1 tales como demencia, esquizofrenia, depresión, dolor (en particular, dolor neuropático o fibromialgia), diabetes (en particular, diabetes mellitus tipo II), la resistencia a la insulina y demás. Se descubrió que un compuesto heterocíclico bicíclico (el heterociclo bicíclico se forma cuando un anillo de ciclohexano se fusiona a un heterociclo monocíclico de
